Nucl Med Mol Imaging.
2018 Jun;52(3):170-189. 10.1007/s13139-017-0500-y.
Radiomics in Oncological PET/CT: Clinical Applications
- Affiliations
-
- 1Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, 25, Simgok-ro 100 Gil 25, Seo-gu, Incheon 22711, South Korea. jwlee223@ish.ac.kr
- 2Institute for Integrative Medicine, International St. Mary's Hospital, Catholic Kwandong University College ofMedicine, Incheon, South Korea.
- 3Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea.
- KMID: 2414808
- DOI: http://doi.org/10.1007/s13139-017-0500-y
Abstract
- ¹â¸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely used for staging, evaluating treatment response, and predicting prognosis in malignant diseases. FDG uptake and volumetric PET parameters such as metabolic tumor volume have been used and are still used as conventional PET parameters to assess biological characteristics of tumors. However, in recent years, additional features derived from PET images by computational processing have been found to reflect intratumoral heterogeneity, which is related to biological tumor features, and to provide additional predictive and prognostic information, which leads to the concept of radiomics. In this review, we focus on recent clinical studies of malignant diseases that investigated intratumoral heterogeneity on PET/CT, and we discuss its clinical role in various cancers.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Combination of 18 F-Fluorodeoxyglucose PET/CT Radiomics and Clinical Features for Predicting Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma
- Radiomics and Deep Learning from Research to Clinical Workflow: Neuro-Oncologic Imaging
- Radiomics in Oncological PET/CT: a Methodological Overview
- The Proper Use of PET/CT in Tumoring Imaging
- 18F-FDG PET/CT Parameters Enhance MRI Radiomics for Predicting Human Papilloma Virus Status in Oropharyngeal Squamous Cell Carcinoma
